Case Report

A Case of Premature Ovarian Failure in a 33-Year-Old Woman

Emma Colao, Teresa Granata, Marco F. M. Vismara, Francesco Bombardiere, Donatella Nocera, Elisa Luciano, Nicola Perrotti, and Paola Malatesta

Medical Genetics Unit, University Hospital “Policlinico Mater Domini”, Magna Graecia University at Catanzaro, Viale Europa, Campus Salvatore Venuta, 88100 Catanzaro, Italy

Correspondence should be addressed to Nicola Perrotti; perrotti@unicz.it and Paola Malatesta, paolissima2@yahoo.it

Received 29 September 2012; Accepted 23 October 2012

Copyright © 2013 Emma Colao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To assess aetiology of a POF in a 33-year-old woman and, if possible, plan a cure. Design. Case report. Setting. medical genetics diagnostic unit in a university hospital. Patient. A 33-year-old woman with premature ovarian failure (POF). Intervention(s). Genetic counseling, karyotyping, FISH study. Result(s). Turner-like diagnosis. Conclusion(s). Most cases of POF remain idiopathic. Turner syndrome can occur in very different phenotypes; cytogenetic and molecular profiling can provide a definitive diagnosis in cases with nonclassical phenotype.

1. Introduction

The average age of the menopause is 50 years [1] with one percent of women menstruating after the age of 60 and one percent entering menopause before the age of 40.

Hereditary and environmental (smoking habit) factors affect the age of the natural menopause. A menopause before the age of 40 is commonly defined as “premature ovarian failure” although this definition is arbitrary. Estimates of the prevalence of premature ovarian failure range between 0.3 and 1% and this condition accounts for 10–28% of women with primary amenorrhea and 4–18% of women with secondary amenorrhea [2] (Table 1).

Some of the causes of POF listed above are extremely rare—particularly the genetic causes. For instance only a few women with FSH-receptor or LH-receptor mutations have ever been reported. In order to give an idea of how common various conditions are, here is a list of the causes of POF in women attending a specialist clinic at the Middlesex Hospital, London, UK (Table 2).

10 to 30% of women with POF already have a concurrent autoimmune disorder the most common of which is hypothyroidism. In the sequence of the most common autoimmune associations found in APSII, ovarian failure can occur at any stage. Thus, a history should include symptoms of Addison’s disease, hypothyroidism, and diabetes in particular with the rarer association of autoimmune arthritides and inflammatory bowel disease being kept in mind. Further, women with established POF should be monitored for the later appearance of these conditions.

The only features of history which are helpful in determining aetiology of ovarian failure are positive a family history, a concurrent autoimmune disorder, or stigmata of one of the inherited conditions. In many instances a formal pedigree enquiry is required to determine other female family members who may be affected, particularly if the inheritance is passed through an unaffected male.

2. Case Presentation

A 33-year-old woman affected by hypergonadotrophic hypogonadism (FSH 71.38 mIU/L; LH 35.50 mIU/L; estradiol <7 pg/mL) had been treated with estroprogestinic therapy “Triminulet” for nine years. Treatment was then suspended to allow a reevaluation of ovarian functionality. Upon drug withdrawal the patient presented secondary amenorrhea and was referred to our unit for an in-depth diagnostic evaluation. A written informed consent was obtained.

Medical history revealed that the patient was born with normal delivery, bottle-fed, and showed standard psychosomatic development, menarche at age of 13 and oligomenorrhea since then up until estroprogestinic therapy was established. Pelvic US demonstrated a normally placed and
Table 1: Causes of premature ovarian failure.

| Diagnosis                                                                 | n  |
|---------------------------------------------------------------------------|----|
| Gonadal dysgenesis                                                        |    |
| Turner’s syndrome                                                         |    |
| Perrault’s syndrome                                                       |    |
| 46, XX gonadal dysgenesis/46, XY gonadal dysgenesis                       |    |
| Genetic associations                                                      |    |
| Familial ovarian failure                                                  |    |
| Galactosaemia                                                             |    |
| Enzyme defects—P450c17                                                    |    |
| FRAXA premutations                                                        |    |
| Blepharophimosis, ptosis, and epicanthus inversus syndrome (also called BPES) |    |
| Small X chromosome defects                                                |    |
| FSH receptor mutations/LH receptor mutations                              |    |
| Autoimmune:                                                               |    |
| Autoimmune Polyendocrinopathy syndrome 1                                  |    |
| APECED/autoimmune Polyendocrinopathy syndrome 2                           |    |
| Association with various autoimmune diseases                              |    |
| Isolated autoimmune ovarian failure                                       |    |
| Iatrogenic chemotherapy                                                   |    |
| Radiotherapy                                                              |    |
| Pelvic surgery                                                            |    |
| Environmental toxins                                                      |    |
| Idiopathic?                                                               |    |

Table 2: Causes of POF in women attending a specialist clinic at the Middlesex hospital, London, UK from [2].

| Diagnosis                                  | n  |
|--------------------------------------------|----|
| Idiopathic POF (no cause found)            | 245|
| Turner’s syndrome                          | 162|
| Autoimmune polyendocrinopathy type 2       | 45 |
| Familial POF                               | 36 |
| Galactosaemia                              | 24 |
| FRAXA premutations                         | 7  |
| BPES                                       | 3  |
| X chromosome breakpoints                    | 3  |
| APS 1/APECED                               | 2  |
| Perrault’s syndrome                        | 1  |

normally developed uterus with a slightly dishomogeneous structure. The ovaries were not visible.

The patient was also affected by autoimmune thyroiditis, treated with levothyroxine. Ten years earlier (2002) the patient received a diagnosis of lactotrophic microadenoma (PRL 125 ng/dL); brain MRI “dubious small area of enhancement in the lower right paramedian pituitary” and was treated with different dosages of cabergoline. This treatment was suspended in August 2010. In 2011 a brain MRI was substantially unmodified compared with with the previous one. In addition the patient reported myopia and arthralgia since she was 15 years old. Family history showed familiarity for thyroid, neurological cardiovascular diseases (see pedigree: Figure 1).

Physical examination: height 158 cm (3rd–25th p), weight 64 Kg (50th p), BMI 25.63 Kg/m², waist circumference 92 cm, cranic, and upper and lower limb measurements between 50th and 75th percentile. No alterations detected in fingers and toes. Apparently a normal development was observed for secondary sex characteristics. Facial features revealed no dysmorphism, however neither mental impairment or cognitive deficit was evident. Vital signs were normal.

A blood sample was drawn in Sodium (Na) heparin coated tube (vacutainer) for mononuclear cells culture and GTG karyotyping. High-definition GTG banding analysis of 100 metaphases (Leica CW4000 software) demonstrated a 45,X (41%)/46,X,rea(X) (59%) mosaicism (Figure 2).

CBG staining of a new lymphocyte preparation demonstrated the presence of two centromeres in the X rearranged population [46,X,rea(X)] (Figure 3). Finally FISH analysis (kit ToTelVysion (TM) Multicolor DNA probe mixtures (Vysis)), confirmed the presence of two X centromeres in rearranged X chromosomes with 2 Xp extremities and no Xq extremity. In the rearranged X chromosome the Xq extremity was substituted by Xp and pericentrometric Xq region. After
FISH analysis the subpopulation previously indicated as 46,X,rea(X) was then redefined as 46,X,idic(X)(q24) (Figure 4).

The final definition of the karyotype as released to the is mos 46,X,idic(X)(q24)?[59]/45,X [41], compatible with a “Turner like” condition that can account for the clinical and endocrinological condition of the patient.

After a written informed consent was obtained from first degree relatives of our patient (parents and sister), a GTG karyotype analysis extended to family members demonstrated that the phenotype observed in our patient was the result of a de novo alteration.

3. Discussion

Turner’s syndrome accounts for most of the cases of nonidiopathic premature ovarian failure [3]. Turner’s syndrome is a syndrome of defective gonadal development in phenotypic females mostly associated with the karyotype 45,X. Patients generally present short stature with gonadal dysgenesis (streak gonads), webbing of the neck, cubitus valgus, elevated gonadotropins, decreased estradiol level in blood, hypothyroidism, congenital heart defects, and primary amenorrhea with failure to develop secondary sex characteristics (sexual infantilism) [4].

Mosaicism accounts for 35% of Turner syndrome cases. 10% of these cases are due to mosaicism for an X isochromosome [5]. Typically, in case of mosaicism, patients may present features that do not satisfy all the characteristics of the syndrome.

The case examined in the paper shows an attenuated phenotype, consistent with an X chromosome mosaicism. Indeed 41% cells have a monosomy of the X chromosome (45,X karyotype). The remaining 59% cells have an isodicentric X chromosome, then presenting a trisomy of Xp, monosomy of Xq24, and partial trisomy of the rest of Xq.

This can explain the atypical phenotype of the patient: even in absence of classical dysmorphic features (pterigio, typical facies, and primary amenorrhea), she still suffers from other peculiar endocrine alterations, like hypergonadotropic hypogonadism, hypothyroidism, and autoimmune phenomena.

Regarding primary amenorrhea, this is not present in our case, although she has undergone to a premature ovarian failure.

Interestingly menarche and ovarian function are essentially regulated by two genes on X chromosome: POF1 and POF2, respectively, located on Xq24-Xq28 and Xq21.33. Based on our karyotype analysis we can say that, in the subpopulation of rearranged X chromosomes, POF1 results deleted, whereas POF2 is present in three copies.

We hypothesize that this peculiar genetic configuration can be sufficient to induce menarche, although POF1 haploinsufficiency is probably inadequate to sustain ovarian function thus leading to secondary amenorrhea.

Another trait typical of Turner’s syndrome is short stature. In this case, patient’s stature is in the lower normal range, included between the 3 and the 25 percentile. The

Figure 3: CBG Karyotype: red arrows show the two centromeres on dicentric X chromosome; blue arrows point to normal chromosomes (one centromere).

Figure 4: FISH images: (a) Aqua probe for X centromeres that demonstrates an X isodicentric subpopulation. (b) Two Orange/Green signals for Xp extremity on the isodicentric X (with two Aqua signals). (c) No Orange/Green signals for Xq in the isodicentric X (Aqua).
position of short stature homeobox gene (SHOX gene) can explain, in part, this phenotypic feature.

The SHOX gene belongs to a family of genes called homeoboxes and is also part of the family of genes called PAR (Pseudoautosomal regions).

SHOX gene is made of seven exons, one of which is noncoding. Homeobox domain is coded by exons 3 and 4, that acts like transcriptional activators. SHOX codes also two alternatively spliced transcripts, SHOXa and SHOXb. The SHOX gene act during early embryonic development to control the formation of many body structures. Specifically, the SHOX gene is essential for the development of the skeleton and plays an important role in growth [6–8] and maturation of bones in the arms and legs.

One copy of the SHOX gene is located on each of the sex chromosomes (the X and Y chromosomes) in an area called the pseudoautosomal region, Xp22.33 and Yp11.3 (Figure 5). Although many genes are unique to either the X or Y chromosome, genes in the pseudoautosomal region are present and are transcriptionally active on both chromosomes. As a result, females (who have two X chromosomes) and males (who have one X and one Y chromosome) have two functional copies of the SHOX gene in each cell.

Because the SHOX gene is located on the sex chromosomes, most women with Turner syndrome have only one copy of the gene in each cell instead of the usual two copies. Loss of one copy of this gene reduces the amount of SHOX protein that is produced. A shortage of this protein likely contributes to the short stature and skeletal abnormalities [9] often seen in females with Turner syndrome [10].

In the case described in the present paper, SHOX gene is triplicated in the cell subpopulation harboring the rearranged X chromosome and this triplication can probably in part correct the haploinsufficiency that is present in the 45,X cells [11] thus mitigating the short stature phenotype that is typical of Turner syndrome.

Authors’ Contribution

E. Colao, T. Granata and Marco F. M. Vismara contributed equally to this work.

Acknowledgments

The authors wish to thank Dr. A. Apa and Dr. MT. Moricca at Pediatrics Department Mater Domini University Hospital of Catanzaro, for their precious help with photographs of FISH images. We wish to thank Dr. ssa A. Apa and Dr. ssa MT. Moricca–Pediatrics Dept, Mater Domini University hospital, Catanzaro–for their precious help with photographs of FISH images and Dott. J. Toaff for proofreading the manuscript.

References

[1] J. P. de Bruin, H. Bovenhuis, P. A. H. van Noord et al., “The role of genetic factors in age at natural menopause,” Human Reproduction, vol. 16, no. 9, pp. 2014–2018, 2001.
[2] D. Goswami and G. S. Conway, “Premature ovarian failure,” Human Reproduction Update, vol. 11, no. 4, pp. 391–410, 2005.
[3] http://www.endocrineonline.org/pdf%20box/pof.pdf, 2012.
[4] http://www.ncbi.nlm.nih.gov/mesh/68014424, 2012.
[5] S. Blachford, Gale Encyclopedia of Genetic Disorders, Thomson Gale, 1st edition, 2002.
[6] G. Day, A. Szvetko, L. Griffiths et al., “SHOX gene is expressed in vertebral body growth plates in idiopathic and congenital scoliosis: implications for the etiology of scoliosis in turner syndrome,” Journal of Orthopaedic Research, vol. 27, no. 6, pp. 807–813, 2009.
[7] A. L. J. Alexander, Y. N. Mirian, M. F. A. Funari et al., “Baixa estatura por haploinsuêciência do gene SHOX: do diagnóstico ao tratamento,” Arquivos Brasileiros de Endocrinologia e Metabolologia, vol. 52, no. 5, pp. 765–773, 2009.

[8] Rosa R. S. Martins, I. B. Ramos Hilda, Juan C. Llerena Jr., and José C.C. Almeida, “Investigação clinica e genética em meninas com baixa estatura idiopática,” Arquivos Brasileiros de Endocrinologia e Metabolologia, vol. 47, no. 6, pp. 684–694, 2003.

[9] A. D. Guedes, B. Bianco, E. Q. Callou, A. L. Gomes, M. V. N. Lipay, and I. T. N. Verreschi, “Growth hormone treatment in turner syndrome: data and reflections,” Arquivos Brasileiros de Endocrinologia e Metabolologia, vol. 52, no. 5, pp. 757–764, 2008.

[10] http://ghr.nlm.nih.gov/gene/SHOX, 2012.

[11] G. del Rey, H. Jasper, S. V. Bengolea, A. Boywitt, R. de Bellis, and J. J. Heinrich, “Trisomy of the short stature homeobox-containing gene (SHOX) due to duplication/deletion of the X chromosome: clinical implications on the stature,” Hormone Research in Paediatrics, vol. 74, no. 4, pp. 297–304, 2010.